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Aims Inflammation is a central process in the pathophysiology of heart failure (HF), but trials targeting tumour necrosis
factor (TNF)-𝛼 were largely unsuccessful. Interleukin (IL)-6 is an important inflammatory mediator and might
constitute a potential pharmacologic target in HF. However, little is known regarding the association between
IL-6 and clinical characteristics, outcomes and other inflammatory biomarkers in HF. We thus aimed to identify
and characterize these associations.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
Interleukin-6 was measured in 2329 patients [89.4% with a left ventricular ejection fraction (LVEF) ≤ 40%] of the
BIOSTAT-CHF cohort. The primary outcome was all-cause mortality and HF hospitalization during 2 years,
with all-cause, cardiovascular (CV), and non-CV death as secondary outcomes. Approximately half (56%) of all
included patients had plasma IL-6 values greater than the previously determined 95th percentile of normal
values at baseline. Elevated N-terminal pro-brain natriuretic peptide, procalcitonin and hepcidin, younger age,
TNF-𝛼/IL-1-related biomarkers, or having iron deficiency, atrial fibrillation and LVEF > 40% independently predicted
elevated IL-6 levels. IL-6 independently predicted the primary outcome [HR (95% confidence interval) per doubling:
1.16 (1.11–1.21), P< 0.001], all-cause mortality [1.22 (1.16–1.29), P< 0.001] and CV as well as non-CV mortality
[1.16 (1.09–1.24), P< 0.001; 1.31 (1.18–1.45), P< 0.001], but did not improve discrimination in previously published
risk models.
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Conclusions In a large, heterogeneous cohort of HF patients, elevated IL-6 levels were found in more than 50% of patients and were
associated with iron deficiency, reduced LVEF, atrial fibrillation and poorer clinical outcomes. These findings warrant
further investigation of IL-6 as a potential therapeutic target in specific HF subpopulations.
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Introduction
Inflammation is a key process in the pathophysiology of heart
failure (HF).1 Increased levels of pro-inflammatory cytokines are
associated with worse outcomes and adverse cardiac remodelling
in patients with HF.1 Although some benefit has been observed
in small studies testing immunomodulatory agents in HF, larger
clinical trials targeting tumour necrosis factor (TNF)-𝛼, including
the ATTACH and RENEWAL trials, were largely unsuccessful, with
even potential detrimental effects at higher doses of infliximab in
ATTACH.1,2 However, the recent Canakinumab Anti-inflammatory
Thrombosis Outcome Study (CANTOS) evaluating the effects of
interleukin (IL)-1𝛽 blockade in patients with previous myocardial
infarction and elevated high sensitivity C-reactive protein (hsCRP),
demonstrated unprecedented benefits in reduced cardiovascular
(CV) risk.3 The results of CANTOS and the accumulating evidence
for the role of inflammation in HF resulted in renewed interest to
investigate anti-inflammatory agents in HF.
Interleukin-6 is a cytokine with both pro-inflammatory and
anti-inflammatory properties.4 The significance of IL-6 in CV dis-
ease has only recently been fully recognized. A large meta-analysis
investigated the Asp358Ala single nucleotide polymorphism (SNP)
of the IL-6 receptor.5 Asp358Ala carriers had a 3.4% reduced risk of
coronary artery disease for each gene copy. This suggests a causal
role for IL-6 signalling in coronary artery disease. Additionally, IL-6
levels are known to increase with age and IL-6 signalling has been
implicated in the pathophysiology of common HF co-morbidities
including frailty, anaemia of chronic disease, renal disease and atrial
fibrillation (AF).6–8
Increased cardiac IL-6 and IL-6 receptor mRNA levels have
been associated with worsening haemodynamics in advanced HF.9
Worsening of HF was also associated with the CG genotype
of the 174G/C SNP of the IL-6 promoter as well as circulating
levels of IL-6, irrespective of left ventricular ejection fraction
(LVEF).10–12 Additionally, significant associations between IL-6
and HF-associated mortality have previously been described in
small HF cohorts.13,14 As such, IL-6 is of special interest in HF as
pharmacological agents targeting IL-6 signalling have already been
developed and successfully used in a multitude of (autoimmune)
diseases (e.g. tocilizumab, sarilumab, siltuxumab) and have recently
been reviewed by Garbers et al.15 Nevertheless, inflammation is a
multifaceted disease process involving a number of major media-
tors and underlying signalling processes. It is therefore of interest
to establish how IL-6 is related to other biomarkers in HF. Previous
studies were limited by their sample size and did not investigate
the association of IL-6 with other such biomarkers. We therefore
aimed to address this by investigating the relationship between IL-6
and clinical characteristics, outcomes and other biomarkers in HF. .
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. Methods
Patients
This is a retrospective study of the BIOSTAT-CHF index cohort.
The characteristics of this cohort have been described previously.16
Briefly, BIOSTAT-CHFwas a multi-centre, multi-national, observational
study composed of an index and a validation cohort; 2516 patients
from 69 centres across 11 European countries were included in
the index cohort on the basis of worsening signs/symptoms and
suboptimal treatment of HF. The primary endpoint was a combined
outcome of all-cause mortality and unscheduled hospitalization for HF.
Secondary endpoints were HF hospitalizations, all-cause and CV vs.
non-CV mortality. Cause-specific outcomes were determined by site
investigators and not independently adjudicated.
Laboratory indices
Measured laboratory values in the index cohort included IL-6,
N-terminal pro-brain natriuretic peptide (NT-proBNP), CRP, procalci-
tonin (PCT), troponin T, haemoglobin, erythrocyte mean corpuscular
volume, complete leucocyte blood count, iron, hepcidin, ferritin,
transferrin, and % transferrin saturation at baseline. The plasma levels
of the following TNF-𝛼/IL-1 related biomarkers were also determined:
ST2, IL-1 receptor type 1/2 (IL-1RT1/IL-1RT2), TNF receptor 2
(TNFR-2) and TNF receptor superfamily members 10c, 13b and 14
(TNFRSF-10c/-13b/-14). The levels of serum creatinine, as well as the
estimated glomerular filtration rate (eGFR) based on the Modification
of Diet in Renal Disease formula were determined at baseline and at
9-month follow-up. Plasma levels of biomarkers were determined
using sandwich or competitive enzyme-linked immunosorbent assays
on a Luminex platform (Singulex Inc., Alere Inc., and Roche Inc.).
Echocardiography measurements
and exercise testing
Standard echocardiography measurements were available for the
majority of patients and were performed 1–2 months before inclusion
in the study. These included among others: left and right ventricular size
and function, wall thickness, lateral and septal annulus tissue velocities
and atrial diameters. All patients underwent a 6-min walk test (6MWT)
at the time of inclusion.
Statistical analysis
Statistical analyses were carried out with STATA v.15 SE and R
v.3.2.3. Normally distributed variables are presented as mean (standard
deviation), non-normally distributed continuous variables as median
(interquartile range), and categorical variables as number (percentage).
Baseline characteristics are presented stratified to quartiles of IL-6. Sta-
tistical significance was considered for P≤ 0.05. Baseline characteristics
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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across IL-6 quartiles were compared using a one-way analysis of vari-
ance (ANOVA), the Kruskal–Wallis test and the Chi-square test,
where appropriate. The primary and secondary endpoints were cen-
sored at 2 years. Proportionality of hazards was assessed based on
standardized Schoenfeld residuals. Cox proportional hazards models
were used to test for a multivariable association of IL-6 with outcomes.
In a forward stepwise manner, we corrected for clinical confounders
including age, sex, body mass index, eGFR, smoking status, alcohol con-
sumption, diabetes mellitus, eGFR < 60mL/min/1.73m2 and history of
any of the following: AF, myocardial infarction, stroke, peripheral arte-
rial disease, chronic obstructive pulmonary disease and hypertension,
the use of angiotensin-converting enzyme inhibitors/angiotensin recep-
tor blockers (ACEi/ARBs), 𝛽-adrenoreceptor blockers (BBs), mineralo-
corticoid receptor antagonists, digoxin, diuretics and loop diuretics.
To investigate whether IL-6 can improve published risk prediction
models for this cohort,16 we tested for an increase in model fit when
adding IL-6 to the BIOSTAT-CHF risk score for the combined end-
point and all-cause mortality, using the likelihood ratio test. The net
reclassification improvement (NRI), integrated discrimination improve-
ment (IDI) and Harrell’s C-statistic were used to assess improvements
in reclassification and discrimination. The risk score includes age, HF
hospitalization in the last year, peripheral oedema, systolic blood pres-
sure, NT-proBNP, haemoglobin, high-density lipoprotein, sodium and
beta-blocker use at baseline for the primary outcome. For mortality
alone, the BIOSTAT-CHF risk score includes age, blood urea nitro-
gen, NT-proBNP, haemoglobin and beta-blocker use at baseline. When
investigating the association of IL-6 with CV and non-CV mortality,
non-CV and CV mortality respectively were used as competing risks.
All-cause mortality was similarly used as competing risk for HF hospi-
talizations. Clinically significant interactions were investigated for the
combined outcome. IL-6 plasma levels were transformed to a log2 scale
to denote a doubling of IL-6 plasma levels per 1-unit change in all
regression models. Based on a multivariable logistic regression analysis,
we identified the strongest predictors of elevated IL-6 levels.
Results
The recruitment period was 24months and median follow-up was
21months. IL-6 plasma levels were measured in 2329 (92.6%)
of the 2516 patients. A comparison of baseline characteristics
between patients with and without IL-6 measurements is pre-
sented in the online supplementary Table S1. Baseline character-
istics for the index cohort with measured IL-6 are presented in
Table 1. Mean age in the cohort was 69± 12 years, 1716 (74%)
patients were male and median IL-6 levels were 5.2 (2.8–10.2)
pg/mL, with 1327 (56.9%) of patients having IL-6 values greater
than the previously reported 95th percentile of normal values
(> 4.45 pg/mL).17 Patients with higher levels of IL-6 were older,
more often had HF with preserved ejection fraction (HFpEF) and
had a higher prevalence of anaemia, diabetes mellitus and AF. Addi-
tionally, patients with higher IL-6 levels were less likely to be
able to perform the 6MWT and had an overall lower distance
covered. This remained the case after multivariable corrections
for demographics, co-morbidities, medication use and New York
Heart Association functional class for both successful completion
of the test [OR (95% confidence interval, CI) per doubling of IL-6:
0.75 (0.69–0.80), P< 0.001], as well as overall distance covered
[B (95% CI) per doubling of IL-6: −27.19 (−31.50 to –22.88), ..
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.. P< 0.001]. Patients with higher IL-6 levels had significantly lower
mean haemoglobin and iron concentrations, in tandemwith moder-
ately lower transferrin levels and noticeable reductions in transfer-
rin saturation. Hepcidin differed significantly between IL-6 quartiles
(P< 0.001) but was higher in the first and last quartile compared
to the intermediate ones. Patients with the highest IL-6 values had
higher median hepcidin values compared to those with the low-
est IL-6 values. Patients with higher IL-6 levels also had on average
lower eGFR and higher levels of NT-proBNP and CRP.
In multivariable logistic regression analysis, having IL-6 lev-
els above the 95th percentile of normal values was indepen-
dently predicted by the logarithms of NT-proBNP [OR (95% CI):
1.30 (1.14–1.49), P< 0.001], PCT [1.31 (1.14–1.51), P< 0.001],
lower iron levels [0.48 (0.38–0.60), P< 0.001] and hepcidin [1.27
(1.14–1.40), P< 0.001], as well as having AF [1.35 (1.03–1.77),
P= 0.028], older age [0.87 (0.76–0.99) per 10 years, P= 0.032]
and HFpEF [1.63 (1.06–2.50), P= 0.027]. Most TNF-𝛼/IL-1 related
biomarkers including ST2, IL-1RT2, TNFR-2, TNFRSF-13b, and
TNFRSF-14 were also independent predictors of IL-6 levels. A for-
est plot with all included predictors in multivariable logistic regres-
sion is presented in Figure 1.
Cox proportional hazards and competing
risk survival regression models for the
primary and secondary outcomes
Patients in the highest quartile of IL-6 experienced the com-
bined outcome twice as much as those in the lowest quartile
at 2-year follow-up (Figure 2). After correcting for confounders,
IL-6 remained significantly associated with the combined outcome
[HR (95% CI): 1.16 (1.11–1.21), P< 0.001]. When correcting for
the BIOSTAT-CHF risk score, higher levels of IL-6 remained associ-
ated with the combined outcome [HR (95% CI): 1.08 (1.03–1.13),
P= 0.001]. Higher levels of IL-6 were equally associated with higher
rates of the mortality alone [HR (95% CI): 1.22 (1.16–1.29),
P< 0.001] as well as death due to non-CV causes [HR (95% CI):
1.31 (1.18–1.45), P< 0.001] and CV causes [HR (95% CI): 1.16
(1.09–1.24), P< 0.001]. No significant interactions were identi-
fied between IL-6 and relevant covariates, when predicting the
combined outcome. All subgroup analyses are presented in the
online supplementary Figure S1. The cumulative incidence func-
tion curves for CV/non-CV mortality and HF rehospitalization are
presented in the online supplementary Figures S2–S4. The propor-
tion of patients with mortality due to CV and non-CV causes did
not differ significantly between the four quartiles of IL-6 (P= 0.27).
However, IL-6 was not a significant predictor of HF hospitalizations
alone.
Interleukin-6 improved the model fit of the BIOSTAT-CHF risk
model for the combined outcome (likelihood ratio test: P= 0.002);
however, this did not lead to significant changes in discrimination
[NRI>50: −0.4%, P= 0.610; IDI: 0.2%, P= 0.031; Harrell’s C base-
line: 0.713 vs. Harrell’s C IL-6: 0.715]. Similar findings were identi-
fied for all-cause mortality (Table 2) [likelihood ratio test: P< 0.001,
NRI>50: 0.3%, P= 0.724; IDI: 0.4%, P= 0.021; Harrell’s C baseline:
0.740 vs. Harrell’s C IL-6: 0.741].
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Forest plot with a multivariable logistic regression model for interleukin (IL)-6 levels above or equal to the 95th percentile of normal
values (≥ 4.45 pg/mL). For New York Heart Association (NYHA) functional class, class I is used as a reference category. Odds ratios and 95%
confidence intervals (CI) are presented next to each variable. The following variables were independent predictors of higher IL-6 levels: younger
age (P= 0.032), the logarithms of N-terminal pro-brain natriuretic peptide (NT-proBNP), procalcitonin, hepcidin, ST2, IL-1 receptor type 2
(IL-1RT2), tumour necrosis factor receptor 2 (TNFR-2), tumour necrosis factor receptor superfamily member 14 (TNFRSF-14) and lower
iron concentrations (P< 0.001 for all), the logarithm of tumour necrosis factor receptor superfamily member 13b (TNFRSF-13b) (P= 0.004)
as well as having atrial fibrillation (AF) (P= 0.028) and heart failure with preserved ejection fraction (P= 0.027). eGFR, estimated glomerular
filtration rate (Modification of Diet in Renal Disease formula); LVEF, left ventricular ejection fraction; SBP, systolic blood pressure; IL-1RT1,
interleukin-1 receptor type 1; TNFRSF-10c, tumour necrosis factor receptor superfamily member 10c.
Figure 2 Kaplan–Meier plot displaying the time to event (combined endpoint) curves for patients in different quartiles of interleukin (IL)-6
levels (the 1st quartile contains the lowest values). The log-rank test was significant (P< 0.001).
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Cox regression models for the prediction of the combined outcome and all-cause mortality and competing
risk regression models for the prediction of heart failure hospitalization, cardiovascular and non-cardiovascular
mortality by each doubling of interleukin-6 [log2(IL-6)]
Model Combined endpoint All-cause mortality Cardiovascular
mortality
Non-cardiovascular
mortality
HF hospitalization
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
a 1.25 (1.20–1.30) <0.001 1.31 (1.25–1.38) <0.001 1.26 (1.19–1.34) <0.001 1.37 (1.24–1.50) <0.001 1.06 (0.99–1.13) 0.069
b 1.19 (1.14–1.23) <0.001 1.23 (1.17–1.30) <0.001 1.18 (1.11–1.25) <0.001 1.33 (1.19–1.47) <0.001 1.03 (0.96–1.10) 0.388
c 1.16 (1.12–1.21) <0.001 1.22 (1.16–1.29) <0.001 1.17 (1.09–1.24) <0.001 1.32 (1.19–1.47) <0.001 1.01 (0.94–1.09) 0.732
d 1.16 (1.11–1.21) <0.001 1.22 (1.16–1.29) <0.001 1.16 (1.09–1.24) <0.001 1.31 (1.18–1.45) <0.001 1.01 (0.94–1.08) 0.833
e 1.08 (1.03–1.13) 0.001 1.14 (1.07–1.20) <0.001 N/A N/A N/A
BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular filtration rate (Modification of Diet in Renal Disease formula); HR, hazard ratio; IDI, integrated
discrimination improvement; IL-6 interleukin-6; NRI, net reclassification index.
Model a: IL-6 as a univariable predictor.
Model b: model a with the addition of age, sex, BMI and eGFR.
Model c: model b with the addition of co-morbidities (smoking status, alcohol consumption, diabetes mellitus, eGFR < 60mL/min/1.73 m2 and history of any of the following:
atrial fibrillation, myocardial infarction, stroke, peripheral arterial disease, chronic obstructive pulmonary disease and hypertension.
Model d: model c with the addition of heart failure medication (angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, 𝛽-adrenoreceptor blockers,
mineralocorticoid receptor antagonists, digoxin, diuretics and loop diuretics).
Model e: the addition of IL-6 to the proportional hazards model for the prediction of the combined outcome already published by our group.16
For model e, although model fit based on the likelihood ratio test was better for both the combined endpoint and all-cause mortality (P = 0.002 and P < 0.001, respectively),
reclassification indices were not significantly improved [combined endpoint: NRI>50: −0.4%, P = 0.610; IDI: 0.2%, P = 0.031; Harrell’s C baseline: 0.713 vs. Harrell’s C log2(IL-6):
0.715; all-cause mortality: NRI>50: 0.3%, P = 0.724; IDI: 0.4%, P = 0.021; Harrell’s C baseline: 0.740 vs. Harrell’s C log2(IL-6): 0.741].
Discussion
In this retrospective study of a large and heterogeneous cohort
of HF patients, approximately half of all patients had abnormally
elevated IL-6 levels based on previously defined normal values.
Having HFpEF and AF as well as younger age, decreasing iron values
and increasing NT-proBNP, PCT, hepcidin and TNF-𝛼/IL-1 related
biomarker values were independent predictors of higher IL-6 levels.
IL-6 also independently predicted a combined endpoint of all-cause
mortality and hospitalization and all-cause as well as cause-specific
mortality individually, but the addition of IL-6 to previous predictive
models for this cohort did not improve risk stratification.
In our study, having HFpEF was a strong independent pre-
dictor of elevated IL-6 levels. These findings are in line with a
previous study, which demonstrated that IL-6 and TNF-𝛼 sig-
nificantly correlated with echocardiographic indices of diastolic
dysfunction and were both shown to downregulate the expres-
sion of sarcoplasmic reticulum Ca2+-ATPase (SERCA2) channels in
cardiomyocytes.18 SERCA2 is involved in diastolic cardiomyocyte
relaxation by mediating calcium reabsorption in the sarcoplasmic
reticulum.18 Additionally, IL-6 increases cardiomyocyte stiffness by
reducing titin phosphorylation.19 These processes might in turn
explain the association of IL-6 with diastolic dysfunction. Having
AF was also an independent predictor of higher IL-6, which is in
agreement with previous studies that support a general involve-
ment of inflammatory processes in the pathophysiology of AF.20 In
contrast to previous studies that have identified elevated IL-6 levels
in older patients,6 there was an independent association between
higher IL-6 and younger age in this cohort. This could perhaps be
explained by alterations in IL-6 trans-signaling that occur with age-
ing and lead to reduction of circulating soluble glycoprotein 130, a .
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. soluble receptor which acts as an inhibitor of IL-6 function.21 As
such, IL-6 might be lower in older individuals with HF because its
biological actions are achieved using smaller concentrations. How-
ever, since no additional information was available regarding plasma
glycoprotein 130 levels or other IL-6 signalling components, this
hypothesis could not be investigated.
Patients with higher levels of IL-6 had a higher prevalence of
anaemia and disturbed indices of iron metabolism, and lower
iron levels were an independent predictor of elevated IL-6 levels.
IL-6 signalling activates the acute phase response in the liver and
hepcidin is an acute phase protein produced as a result.4,22 Hepcidin
controls systemic iron metabolism and causes hypoferremia, which
is mediated by IL-6.23 IL-6 also induces a significant increase in
the expression of hepcidin mRNA, independent of IL-1 or TNF-𝛼
activity.22 Anaemia plays an important role in HF as it has been
shown to be associated with a poor prognosis and can affect
exercise capacity, the development of depression and potentially
the myocardium directly.24 Previous studies in chronic HF found
no association between IL-6 and hepcidin levels but were limited
in sample size.24 Our data, taken together with previous studies,
suggest that IL-6 signalling is an important biological pathway
leading to anaemia and/or iron deficiency in HF and might thus
warrant future investigation as a potential treatment target for
modulating these pathologic processes.
NT-proBNP was also a significant independent predictor of ele-
vated IL-6 levels. NT-proBNP is produced in response to cardiac
stretch,25 and experimental evidence has indeed demonstrated
that stretched cardiomyocytes and cardiac fibroblasts elaborate
TNF-𝛼/IL-6 and IL-1𝛽, respectively.19 This is also in agreement
with the finding that elevated IL-6 levels are independently pre-
dicted by higher TNF-𝛼/IL-1 related biomarkers. PCT was an
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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additional independent predictor of elevated IL-6 levels. PCT is
the prohormone of calcitonin, it is mainly produced by the liver
and has been shown to behave as an acute phase protein, inducible
by both TNF-𝛼 and IL-6; its primary biological action is similar
to mature calcitonin and involves the reduction of blood calcium
levels.26 In addition, PCT acts as a chemokine at sites of injury
and has been shown to induce inflammatory cytokine production
in macrophages, the principal immune cells that produce IL-6.27
Current opinion supports an association of elevated PCT levels
with infectious processes. However, up to a third of patients
with chronic kidney disease may have abnormally elevated PCT,
which resolves after the initiation of renal replacement therapy.28
This suggests an additional role of PCT in chronic inflammatory
conditions, which might by extension also apply to HF.
Previous studies have demonstrated that IL-6 significantly pre-
dicted mortality in acute HF and acute coronary syndromes as
well as chronic HF, although in relatively small cohorts (75 and
102 patients, respectively).13,14 In another study, elevated plasma
IL-6 was associated with an increased risk of death and higher
urine IL-6 levels were associated with a higher risk of having
eGFR< 60mL/min/1.73m2.7 To our knowledge, our study is the
first to incorporate IL-6 in a validated risk prediction model
for all-cause mortality and hospitalization in a multi-national and
diverse HF population, with an adequate sample size. We demon-
strated that each doubling of IL-6 independently predicted HF hos-
pitalization and all-cause as well as cause-specific mortality. We also
demonstrate that plasma IL-6 proportionally increases as eGFR
decreases. However, IL-6 did not improve previously published risk
models for this cohort.
Clinical implications of interleukin-6
levels in heart failure
Firstly, having HFpEF, AF, iron deficiency and increased NT-proBNP,
PCT, hepcidin and TNF-𝛼/IL-1 related biomarker levels were inde-
pendent predictors of higher IL-6 levels and IL-6 was associated
with various indices of iron metabolism. As mentioned previously
specifically for iron deficiency, previous basic studies have demon-
strated that the effects of IL-6 are independent of TNF-𝛼/IL-1.22
The latter, together with a study demonstrating that longstand-
ing TNF-𝛼 blockade in rats with HF leads to reactive elevation
of plasma IL-6,29 might constitute a potential explanation as to
why TNF-𝛼 blockade has thus far failed to demonstrate beneficial
effects in patients with HF. Although our findings do not permit for
causal inferences to be drawn, they do warrant further investiga-
tion of any potential pharmaceutical applications of IL-6 signalling
modulation in future studies. Lastly, IL-6 was an independent pre-
dictor of adverse events, although it did not improve discrimination
in previously published risk models for this cohort. However, it
should be noted that these models included haemoglobin as well
as NT-proBNP, which may both change in tandem with IL-6 levels
and may thus account for the variance explained by IL-6. In this
study, we identified a strong relationship between IL-6 and indices
of iron metabolism, which could lead to incorrect deductions due
to multicollinearity. ..
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.. Limitations
In this retrospective study, we only investigated the associations
of IL-6 plasma levels with clinical characteristics, other inflamma-
tory biomarkers and outcomes. No data were currently available
on genetic expression parameters or other proteomic markers
of IL-6 signalling. As a result, other signalling components such
as glycoprotein 130 and the soluble IL-6 receptor were not inves-
tigated next to plasma IL-6. Furthermore, we did not directly eval-
uate TNF-𝛼/IL-1 themselves in relation to IL-6 and no longitudinal
data on IL-6 levels were available. Additionally, no data on the
prevalence of autoimmune disease in this cohort were available.
Finally, although numerous associations were identified between
IL-6 and clinical measurements/outcomes, these require further
individual, dedicated investigation in future studies.
Conclusion
In a large cohort of HF patients, approximately half had IL-6 levels
above the 95th percentile of normal values. Independent predic-
tors of IL-6 were the presence of younger age, HFpEF, AF, iron
deficiency and higher NT-proBNP, PCT, hepcidin and TNF-𝛼/IL-1
related biomarker levels. Finally, plasma levels of IL-6 independently
predicted death and/or HF hospitalization but did not improve
discrimination in previous models. These findings suggest an impor-
tant, albeit limited, role for IL-6 as an adjunct for risk stratification
in HF and constitute preliminary evidence that warrants further
investigation of any potential pharmaceutical applications of IL-6
signalling modulation and especially in specific target groups, such
as patients with elevated IL-6 or patients with HFpEF, AF, or iron
deficiency. Nevertheless, these results should be individually vali-
dated in future studies that can support causal inferences.
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